黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Combined venetoclax and alvocidib in acute myeloid leukemia.

Oncotarget. 2017; 
Bogenberger James,Whatcott Clifford,Hansen Nanna,Delman Devora,Shi Chang-Xin,Kim Wontak,Haws Hillary,Soh Katherine,Lee Ye Sol,Peterson Peter,Siddiqui-Jain Adam,Weitman Steven,Stewart Keith,Bearss David,Mesa Ruben,Warner Steven,Tibes R
Products/Services Used Details Operation
Peptide Synthesis ; Abcam), and β-actin (A00702; GenScript). Densitometry was performed with Image J software Get A Quote

摘要

More effective treatment options for elderly acute myeloid leukemia (AML) patients are needed as only 25-50% of patients respond to standard-of-care therapies, response duration is typically short, and disease progression is inevitable even with some novel therapies and ongoing clinical trials. Anti-apoptotic BCL-2 family inhibitors, such as venetoclax, are promising therapies for AML. Nonetheless, resistance is emerging. We demonstrate that venetoclax combined with cyclin-dependent kinase (CDK) inhibitor alvocidib is potently synergistic in venetoclax-sensitive and -resistant AML models , and . Alvocidib decreased MCL-1, and/or increased pro-apoptotic proteins such as BIM or NOXA, often synerg... More

关键词

BCL-2,acute myeloid leukemia (AML),alvocidib/flavopiridol,venetoclax/ABT